Some clinicians may choose to initiate treatment of atopic dermatitis with topical corticosteroids and make a transition to topical calcineurin inhibitors when the extent of the inflammation is ...

AD, The most common inflammatory skin disorder worldwide, is a highly heterogeneous condition with current treatments that do not address the multiple inflammatory pathways that cause its specific ...

Individuals on immunosuppressants should discontinue them prior to patch testing, if at all possible, to avoid tarnishing the test results, according to updated guidelines from the North American ...

"For a long time, those with atopic dermatitis, like Greg Blankenship, had to be treated with steroids," Muennich said. "It's pretty chronic, no great cure, but we do have newer treatments." ...

Opens in a new tab or window Members of an international team of experts in atopic dermatitis (AD ... home messages for dermatologists? Treatment is best initiated through shared decision-making ...

This article also looks at causes, treatment options, and more. Atopic dermatitis ... It is best to contact your doctor if you exerience symptoms of dermatitis, or if existing symptoms worsen.

Even dogs can suffer from dermatitis. That's right: just like for us humans, it is a rather common skin disease.

This achievement further emphasises the drug’s efficacy across multiple indications, including atopic dermatitis (AD ... for competition in AD treatment and may introduce a novel therapeutic ...

“We believe STAR-0310 will be the best-in-class therapy due to efficacy ... antagonist in clinical development for the treatment of atopic dermatitis. Learn more about our company on our ...

Incyte’s ruxolitinib franchise, made up of blockbuster JAK inhibitor Jakafi and its topical counterpart Opzelura, have been ...

Jonathan Wolleben, an analyst from JMP Securities, has initiated a new Buy rating on Astria Therapeutics (ATXS).Invest with Confidence: Follow ...

“As we increase the number of patients, we remain excited by the outlook for our Phase 1 clinical trial of soquelitinib for the treatment of atopic dermatitis,” said Richard A ...